Hostname: page-component-6bf8c574d5-8gtf8 Total loading time: 0 Render date: 2025-02-19T09:43:13.830Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of long-acting injectable paliperidone 3 monthly and aripiprazol 1 monthly on hospitalization rate in a first-episode psychosis

Published online by Cambridge University Press:  13 August 2021

P. Gil Lopez ,
J.M. Rodriguez Sanchez ,
L. Garcia Fernandez  and
V. Sanchez Estevez
P. Gil Lopez*
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
J.M. Rodriguez Sanchez
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
L. Garcia Fernandez
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
V. Sanchez Estevez
Affiliation:
Early Intervention Service For First Psychotic Episodes “lehenak”, Mental Health Network of Bizkaia (RSMB). Basque Health System. Osakidetza, Bilbao, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Long-acting injectable antipsychotics (LAIs) can reduce relapse and hospitalization risk but they are not widely used in first psychotic episode (FEP) patientes.

Objectives

To examine the effcacy of two of the most used second generation LAI antipsychotics (paliperione 3 monthly and aripiprazol 1 monthly) to reduce hospitalization rates.

Methods

We evaluated in a naturalistic study a sample of patients (n=277) with a FEP. We carried out a mirror-design study to compare the number of hospitalizations and days in hospital before and after the introduction of LAI paliperidone (3 monthly) or LAI aripiprazol. In our Early Intervention Services (Lehenak) antipsychotic treatment is not protocolized and is established for each patient according to the psychiatrist criteria.

Results

We review the oucome of 277 FEP treated in our Early Intervention Service “Lehenak” with LAI paliperidone 3 monthly (n=156) or LAI Aripiprazol (n=121)

Pre LAI Mirror PeriodPost LAI Mirror PeriodWithin group comparisons (paired t-test) t p
Aripiprazol LAI number of Hospitalizations (mean, standard deviation)2.31 (1.72)0.73 (1.23)17.4 (<0.001)
Paliperidone LAI 3 monthly number of Hospitalizations number0,68 (0.93)0.15 (0.47)4.62 (<0.001)
Aripiprazol LAI Days in Hospital30.26 (33.52)17.02 (38.19)2.93 (0.004)
Paliperidone LAI 3 monthly Days in hospital12.63 (24.23)3.40 (14.18))7.5 (<0.001)

Conclusions

Both LAI paliperidone 3 monthly and LAI aripiprazol had a postive impact on hospitalIzation rate, decreasing them significantly after their introduction. These data also support a more extensive use of LAI paliperidone 3 monthly in FEP.

Disclosure

Presenting author has received honouraria for lectures or advisory boards from Janssen, Otsuka, Lundbeck and Angelini in the last five years

Keywords

first-episode psychosisRelapse preventionlong-acting aripiprazollong-acting paliperidone
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S812
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.